Nowadays, novel therapies that target the EGFR agents have improved patient’s therapies with colorectal, lung, head and neck and pancreatic cancers; however, there are some cases using monoclonal antibodies where an activation of signaling pathways downstream of the EGFR could produce resistance to the treatment [61,62]. The gene discussed is EGFR; the disease is pancreatic neoplasm.